Loading clinical trials...
Loading clinical trials...
A Randomized, Blinded, Multi-site, Pilot Study to Evaluate Adenosine 2A Receptor Agonist (REGADENOSON) in the Rehabilitation of Marginal Donor Lungs.
Conditions
Interventions
Regadenoson
Placebo
Locations
2
United States
University of Maryland Medical Center
Baltimore, Maryland, United States
Cleveland Clinic
Cleveland, Ohio, United States
Start Date
June 22, 2020
Primary Completion Date
June 23, 2024
Completion Date
July 31, 2024
Last Updated
August 5, 2024
NCT07046910
NCT05837663
NCT07235683
NCT06990711
NCT07291258
NCT02812290
Lead Sponsor
University of Maryland, Baltimore
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions